Precision Biosciences (DTIL) Non-Current Deffered Revenue (2018 - 2025)

Precision Biosciences (DTIL) has 8 years of Non-Current Deffered Revenue data on file, last reported at $20.0 million in Q3 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 24.92% year-over-year to $20.0 million in Q3 2025; TTM through Sep 2025 was $20.0 million, a 24.92% decrease from a year earlier, with the FY2024 full-year figure at $23.3 million, down 68.12% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $20.0 million, down from $20.2 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for DTIL reached as high as $131.2 million in Q1 2021 and fell as low as $20.0 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $63.6 million across 5 years, with a median of $73.1 million in 2023.
• Across the five-year window, Non-Current Deffered Revenue surged 99.05% in 2021 and plunged 72.58% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $67.0 million in 2021, then advanced by 23.66% to $82.9 million in 2022, then dropped by 11.81% to $73.1 million in 2023, then plunged by 68.12% to $23.3 million in 2024, then dropped by 14.35% to $20.0 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $20.0 million in Q3 2025, $20.2 million in Q2 2025, and $20.5 million in Q1 2025.